Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapy for chronic hepatitis B. Present status.

M Rizzetto1

  • 1Cattedra di Gastroenterologia, Università degli Studi--Torino.

Minerva Gastroenterologica E Dietologica
|February 25, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of hepatitis D: an unmet medical need.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2020
Same author

Letter: HBsAg kinetics-guided interferon therapy for chronic hepatitis D - authors' reply.

Alimentary pharmacology & therapeutics·2017
Same author

HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response.

Alimentary pharmacology & therapeutics·2016
Same author

Hepatorenal syndrome after treatment of visceral leishmaniasis requiring terlipressin therapy.

Minerva gastroenterologica e dietologica·2015
Same author

Antiviral treatment discontinuation among hepatitis C-infected individuals with thrombocytopenia.

Journal of viral hepatitis·2015
Same author

Letter: renal effects of tenofovir in adefovir dipivoxil-experienced HBV patients.

Alimentary pharmacology & therapeutics·2014
Same journal

Hepatic steatosis integrated approach: nutritional guidelines and joined nutraceutical administration.

Minerva gastroenterologica e dietologica·2021
Same journal

Diagnostic accuracy of computerized tomography (CT) angiography in detecting non-variceal gastrointestinal bleeding (NVGIB): a sistematic review.

Minerva gastroenterologica e dietologica·2020
Same journal

Helicobacter pylori and non-alcoholic fatty liver disease.

Minerva gastroenterologica e dietologica·2020
Same journal

Hypertriglyceridemic pancreatitis.

Minerva gastroenterologica e dietologica·2020
Same journal

Effectiveness of percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis.

Minerva gastroenterologica e dietologica·2020
Same journal

Noninvasive diagnosis of fibrosis in non-alcoholic fatty liver disease: diagnostic accuracy of different scores.

Minerva gastroenterologica e dietologica·2020
See all related articles

Interferon (IFN) is limited for chronic viral hepatitis. Lamivudine shows promise but requires combination therapy to overcome resistance and improve outcomes for Hepatitis B Virus (HBV) and Hepatitis D Virus (HDV) infections.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Interferon (IFN) is the sole licensed therapy for chronic viral hepatitis B and D.
  • IFN monotherapy has limited efficacy and significant side effects, particularly for HBeAg-positive chronic hepatitis B.

Purpose of the Study:

  • To evaluate the efficacy of combination therapies and novel antivirals for chronic viral hepatitis.
  • To address the limitations of Interferon monotherapy and explore alternatives for Hepatitis B Virus (HBV) and Hepatitis D Virus (HDV) treatment.

Main Methods:

  • Review of existing literature on combination therapies (e.g., with acyclovir, levamisole, cortisone) and direct-acting antivirals.
  • Assessment of clinical benefits, safety, and tolerance of antivirals like Adenine Arabinoside monophosphate, Famciclovir, and Lamivudine.

Related Experiment Videos

  • Analysis of Lamivudine's activity against wild-type HBV and HBeAg-minus variants, including resistance mutations.

    • Main Results:

    • Combination therapies with acyclovir, levamisole, and cortisone offered no advantage over IFN alone.
    • Adenine Arabinoside monophosphate showed neurotoxicity; Famciclovir lacked significant efficacy.
    • Lamivudine demonstrated clinical benefit, safety, and tolerance, repressing HBV during therapy.
    • Lamivudine withdrawal resulted in relapse in some patients, and long-term use led to emergence of resistant polymerase gene mutants.
    • No effective therapy currently exists for chronic HDV hepatitis; IFN is largely ineffective.

    Conclusions:

    • Lamivudine is a promising antiviral for chronic HBV, but its efficacy is limited by resistance.
    • Combination therapy with agents targeting Lamivudine escape mutants offers new therapeutic avenues.
    • Effective treatment for chronic HDV hepatitis remains an unmet need.